Best Small Cell Lung Cancer Treatment Podcasts (2025)

1
A Podcast on Real-World Evidence with Avelumab First-Line Maintenance and Treatment Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma 43:35

Play Pause

11d ago43:35

43:35

Avelumab first-line maintenance is an approved treatment for cisplatin-eligible or -ineligible patients with advanced urothelial carcinoma (UC) who are progression free following first-line platinum-based chemotherapy, based on the results of the... Avelumab first-line maintenance is an approved treatment for cisplatin-eligible or -ineligible patie…

1
A Podcast on Integrating Genetic Testing for Homologous Recombination Repair Gene Alterations in Patients with Prostate Cancer in the USA: a Multidisciplinary Approach to Overcoming the Obstacles 21:19

13d ago21:19

21:19

In this podcast, Dr. Brittany M. Szymaniak from the Feinberg School of Medicine at Northwestern University, Chicago, IL, USA, Dr. Alicia K. Morgans from the Dana-Farber Cancer Institute, Boston, MA, USA, and Dr. Neal D. Shore from the Carolina... In this podcast, Dr. Brittany M. Szymaniak from the Feinberg School of Medicine at Northwestern Univers…

1
S2 Ep34: PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS) 26:04

19d ago26:04

26:04

Episode Description In this podcast, ALS expert Terry Heiman-Patterson, MD, discusses best practices for ALS diagnosis and use of targeted therapy. Learning Objectives Upon successful completion of this activity, you should be better prepared to: Apply recommended diagnostic criteria and strategies to make an early, accurate diagnosis of ALS Discus…

1
S2 Ep33: PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS) 24:46

19d ago24:46

24:46

Episode Description In this podcast, ALS expert clinician-researcher Richard Bedlack MD, PhD, discusses targeted therapy for ALS and the role of individualized, multidisciplinary care to optimize patient outcomes. Learning Objectives Upon successful completion of this activity, you should be better prepared to: Discuss the mechanisms of action, eff…

1
Dermatologic Adverse Event Mitigation and Management Strategies with Amivantamab + Lazertinib Therapy for Advanced Non-Small Cell Lung Cancer 23:30

21d ago23:30

23:30

In this podcast, Dr. Danny Nguyen from the City of Hope, Huntington Beach, CA, USA, and Dr. Edgardo S. Santos from the Oncology Institute of Hope and Innovation, Broward County, FL, USA, aim to educate on strategies to mitigate and manage dermatologic... In this podcast, Dr. Danny Nguyen from the City of Hope, Huntington Beach, CA, USA, and Dr. Edg…

1
S2 Ep32: Breaking Barriers in HER2-Mutant NSCLC: Exploring the Promise of Next-Generation TKIs 26:11

22d ago26:11

26:11

Episode Description In this episode of the PER® podcast, we explore the evolving landscape of HER2-mutant non–small cell lung cancer (NSCLC)—a rare and historically difficult-to-treat subset of lung cancer. Join Millie Das, MD, from Stanford/VA Palo Alto; and Eric Kumar Singhi, MD, from The University of Texas MD Anderson Cancer Center; as they del…

1
S2 Ep31: Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies 1:04:32

1M ago1:04:32

1:04:32

Episode Description In this podcast, experts Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO, and Fred Hirsch, MD, PhD, review the evolving treatment landscape for limited-stage small-cell lung cancer (LS-SCLC) and extensive-stage (ES) SCLC, including a discussion of the latest strategies for managing common and severe treatment-related adverse events.…

1
S2 Ep30: Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer 1:26:00

1M ago1:26:00

1:26:00

Episode Description This PER® Show Me Your Care Plan!™ featured podcast brings together two medical oncologists and an oncology nurse to discuss the latest advances in the management of platinum-resistant ovarian cancer (PROC). The expert panel reviews current and emerging therapies, with a special focus on the management of adverse events associat…

1
Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis

1M ago

—

Host: Jacob Sands, MD Guest: Elaine Shum, MD Guest: Estelamari Rodriguez, MD, MPH There was a recent pooled analysis of the TROPION-Lung01 and TROPION-Lung05 studies, which focused on the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients with previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC). According t…

1
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities 35:15

1M ago35:15

35:15

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including: Key Comorbidit…

1
Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion 38:06

2M ago38:06

38:06

· In this podcast, the authors discuss the current therapeutic landscape of NSCLC with actionable alterations and provide their perspectives on treatment algorithms, and how to optimally sequence therapies... · In this podcast, the authors discuss the current therapeutic landscape of NSCLC with actionable alterations and provide their perspectives …

1
Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications 21:54

2M ago21:54

21:54

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers. Toxicity Profiles of HER2-Targeted ADCs: Common and…

1
Increasing Awareness of Soft-Tissue Sarcoma: Podcast of a Patient–HCP Discussion 40:33

2M ago40:33

40:33

· In this podcast a patient with sarcoma and a specialist sarcoma nurse discuss the patient’s journey from initial diagnosis through to treatment and recovery. They will also discuss the physiological, emotional and mental... · In this podcast a patient with sarcoma and a specialist sarcoma nurse discuss the patient’s journey from initial diagnosis…

1
Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies 29:36

2M ago29:36

29:36

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, explore the mechanisms of HER2-targeted antibody–drug conjugates (ADCs) and emerging clinical data with these agents across genitourinary, gastrointestinal, and gynecologic cancers. Mechanisms of action of ADCs: how ADCs selective…

1
Burnout Among Physicians Treating Patients with Multiple Sclerosis in the United States: A Podcast 13:51

3M ago13:51

13:51

A podcast focusing on burnout among physicians that treat patients with multiple sclerosis. This podcast is published open access in Neurology and Therapy and is fully citeable. You can access the original published podcast article through the... A podcast focusing on burnout among physicians that treat patients with multiple sclerosis. This podcas…

1
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer 18:34

3M ago18:34

18:34

In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3 Overview of the structure of antibody-drug conjugates (ADCs) Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-…

1
The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies 14:09

3M ago14:09

14:09

In this episode, Zev A. Wainberg, MD; Funda Meric-Bernstam, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explore testing for HER2 alterations and the incidence of HER2-positive disease in the treatment of genitourinary, gastrointestinal, and gynecologic malignancies. HER2 Testing in Advanced Cancers: Recommendations for when and how …

1
Shared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A Vodcast 31:03

3M ago31:03

31:03

Shared decision-making is essential to the care of patients with advanced renal carcinoma which can empower patients and help the healthcare team understand the patient’s goals of care. Identification and management of treatment-related... Shared decision-making is essential to the care of patients with advanced renal carcinoma which can empower pa…

1
Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC 14:42

4M ago14:42

14:42

In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including: Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastu…

1
CIBMTR Registry Data on Inotuzumab Ozogamicin Treatment in Patients with ALL Who Proceeded to Hematopoietic Stem Cell Transplant—A Podcast 18:23

4M ago18:23

18:23

In this podcast, Dr. Marcos de Lima from the Ohio State University, Columbus, OH, USA, and Dr. David I. Marks from the University Hospitals Bristol NHS Trust, Bristol, UK, discuss real-world data obtained from the Center for International Blood and...In this podcast, Dr. Marcos de Lima from the Ohio State University, Columbus, OH, USA, and Dr. Davi…

1
S7 Ep1: The Importance of Spotting Endometrial Cancer 10:25

4M ago10:25

10:25

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.By CURE Talks Cancer

1
S2 Ep29: Oncology PER® Spectives™: Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma 30:09

4M ago30:09

30:09

By PER® Spectives

1
Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer 45:08

5M ago45:08

45:08

In this episode, Jame Abraham, MD, FACP; William J. Gradishar, MD, FACP, FASCO; and Laura Spring, MD, review key insights and frequently asked questions related to the CDK4/6 inhibitors used to treat patients with early and metastatic hormone receptor (HR)–positive/HER2-negative breast cancer from a live program held in January 2025. Key clinical p…

1
Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting 20:01

5M ago20:01

20:01

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including: Early results with teclistamab combined with anti-CD38 therapy Real-world data with teclistamab including its use aft…

1
S2 Ep28: Oncology PER® Spectives™: Oncology Consultations®: Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases 29:33

5M ago29:33

29:33

By PER® Spectives

1
S2 Ep27: Oncology PER® Spectives™: Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision Making and Future Therapies 52:01

5M ago52:01

52:01

By PER® Spectives

1
Rhythms of Healing: Patient and Physician Insights on Art, Music, Dance Therapy and Creativity in Parkinson's Disease 33:19

6M ago33:19

33:19

A podcast to provide an insight in to how art, music, dance therapy and creativity can help alleviate the symptoms of Parkinson's Disease. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International... A podcast to provide an insight in to how art, music, dance therapy and creativity can help alleviate …

1
S2 Ep26: Cases & Conversations: Integrating Novel Approaches to Treatment in First-Line ALK+ mNSCLC Enhancing Patient Outcomes with Real World Multidisciplinary Strategies 41:10

6M ago41:10

41:10

By PER® Spectives

1
Bosutinib for the Treatment of CML—Using it Safely: a Podcast 29:40

6M ago29:40

29:40

In this podcast, Dr. Jeffrey H. Lipton, from the Princess Margaret Cancer Centre, Toronto, ON, Canada, and Dr. Jorge E. Cortes from the Georgia Cancer Centre, Augusta, GA, USA, summarize data from some recent bosutinib publications and discuss... In this podcast, Dr. Jeffrey H. Lipton, from the Princess Margaret Cancer Centre, Toronto, ON, Canada, …

1
S2 Ep25: Oncology PER® Spectives™: Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations 57:25

6M ago57:25

57:25

By PER® Spectives

1
S2 Ep24: Oncology PER® Spectives™: Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma 44:42

6M ago44:42

44:42

By PER® Spectives

1
S2 Ep23: Oncology PER® Spectives™: PSMA in Prostate Cancer: Precision Medicine in Imaging & Therapy 50:18

6M ago50:18

50:18

By PER® Spectives

1
Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer 36:04

6M ago36:04

36:04

In this episode, listen to Virginia Kaklamani, MD, DSc; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, share their clinical insights and takeaways from a live symposium, including from key abstracts presented at the 2024 San Antonio Breast Cancer Symposium: Estrogen receptor mutations in patients With HR-positive/HER2-negative advanced breast ca…

1
A Podcast on Patient and Physician Perspectives in the Holistic Care of Heart-Related Challenges of Type 2 Diabetes 23:42

6M ago23:42

23:42

This podcast is published open access in Diabetes Therapy and is fully citeable. You can access the original published podcast article through the and by using this link: . All conflicts of interest can be found online. This podcast is... This podcast is published open access in Diabetes Therapy and is fully citeable. You can access the original pu…

1
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings

6M ago

—

Host: Jacob Sands, MD Guest: Julia Rotow, MD In non-squamous non-small cell lung cancer (NSCLC), a small percentage of patients will have activating HER2 mutations. For these patients, the standard second-line therapy is docetaxel, but this can have poor response rates. That’s why the DESTINY-Lung03 trial examined the safety and efficacy of trastuz…

1
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers

6M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Laura Alder, MD The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and substantial toxicity. But given the complex structure of ADCs, it’s important to ident…

1
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results

7M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Thomas Egenod, MD In an effort to identify additional treatment options for resectable non-small cell lung cancer (NSCLC), the NeoCOAST-2 study is evaluating the efficacy and safety of combining durvalumab, chemotherapy, and novel agents in the neoadjuvant setting as well as combining durvalumab with …

1
Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial

7M ago

—

Host: Jacob Sands, MD Guest: Alex Spira, MD, PhD, FACP Valemetostat is a novel therapy that’s demonstrated clinical efficacy and safety across multiple hematologic malignancies, but what role might it have in treating patients with advanced, unresectable, or metastatic non-squamous non-small cell lung cancer (NSCLC)? To find out, an upcoming trial …

1
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases

7M ago

—

Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That’s why the phase 3 TROPION-Lung01 trial examined the efficacy and safety of datopotamab deruxtecan (Dato-DXd) for advanced non-squamous NSCLC with brain metastases. Joining Dr. Jacob Sands to share …

1
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01

7M ago

—

Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Docetaxel alone or in combination with ramucirumab is the current standard of care for the second-line treatment of non-small cell lung cancer (NSCLC), but there are several limitations of docetaxel-containing regimens. That’s why there’s interest in identifying new therapies like datopotamab deruxteca…

1
S2 Ep22: PsychPearls Podcast: Optimizing the Management of Tardive Dyskinesia – Addressing the Complexity of Care with Targeted Treatment 11:09

7M ago11:09

11:09

Tardive dyskinesia (TD), a neurological disorder characterized by involuntary movement, is commonly associated with exposure to antipsychotic medication. The disorder can have significant impacts on patient quality of life due to functional challenges and social stigmatization. Comprehensive assessment of TD burden and severity is needed to guide t…

1
A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases 48:50

7M ago48:50

48:50

The incidence of brain metastases is higher in patients with non-small cell lung cancer (NSCLC) than in patients with most other cancers, and the development of brain metastases is associated with poor prognosis. The objective of the podcast is to... The incidence of brain metastases is higher in patients with non-small cell lung cancer (NSCLC) tha…

1
Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) DLBCL with CAR T Cell Therapy: A Vodcast and Case Example 18:35

7M ago18:35

18:35

Authors Gloria Iacoboni and María Pérez Raya outline the management of a patient receiving Chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL). CAR T-cell therapy is effective in the... Authors Gloria Iacoboni and María Pérez Raya outline the management of a patient receiving Chimeric a…

1
NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker

7M ago

—

Host: Jacob Sands, MD Guest: Marina Garassino, MD Datopotamab deruxtecan (Dato-DXd) is a second-line antibody drug conjugate that could lead to improved progression-free survival in patients with advanced or metastatic non-small cell lung cancer. Given these potential benefits, it’s important to identify biomarkers that may predict a patient’s resp…

1
S2 Ep21: Burst CME™: Tackling Adverse Events with Targeted Therapies for Diffuse B-cell Lymphoma 33:30

7M ago33:30

33:30

By PER® Spectives

1
S2 Ep20: Burst CME™: Tackling Adverse Events with Targeted Therapies for Diffuse B-cell Lymphoma 29:35

7M ago29:35

29:35

By PER® Spectives

1
S2 Ep19: Burst CME™: Treating Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Current Options and Emerging Approaches 29:49

7M ago29:49

29:49

By PER® Spectives

1
S2 Ep18: Biomarkers in Diffuse Large B-cell Lymphoma: Empowering Treatment Decisions to Improve Outcomes 29:35

8M ago29:35

29:35

By PER® Spectives

1
S2 Ep17: Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis 43:34

8M ago43:34

43:34

By PER® Spectives

1
Patient and Physician Perspectives of Diabetic Retinopathy and Diabetic Macular Edema Diagnosis, Treatment and Progression: A Podcast Article 37:45

8M ago37:45

37:45

This podcast is published open access in Ophthalmology and Therapy and is fully citeable. You can access the original published podcast article through the Ophthalmology and Therapy website and by using this link: All conflicts of interest can be... This podcast is published open access in Ophthalmology and Therapy and is fully citeable. You can ac…